One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Patent number: 11534409Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.Type: GrantFiled: December 22, 2021Date of Patent: December 27, 2022Assignee: Clexio Biosciences Ltd.Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
-
Patent number: 11517524Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.Type: GrantFiled: December 23, 2021Date of Patent: December 6, 2022Assignees: BioXcel Therapeutics, Inc., ARx, LLCInventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
-
Patent number: 11505556Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.Type: GrantFiled: December 12, 2018Date of Patent: November 22, 2022Assignee: Xalud Therapeutics, Inc.Inventors: Raymond A. Chavez, Stephen Collins
-
Patent number: 11497711Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.Type: GrantFiled: December 23, 2021Date of Patent: November 15, 2022Assignees: BioXcel Therapeutics, Inc., ARx, LLCInventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
-
Patent number: 11464772Abstract: The invention provides methods for treating chronic and acute pain. For example, the invention provides methods of treating neuropathic and inflammatory pain.Type: GrantFiled: October 8, 2018Date of Patent: October 11, 2022Assignee: Blue Therapeutics, Inc.Inventors: Ajay Yekkirala, David Roberson, Michio Painter
-
Patent number: 11446293Abstract: Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process.Type: GrantFiled: March 13, 2020Date of Patent: September 20, 2022Assignee: SpecGX LLCInventors: Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
-
Patent number: 11433063Abstract: Nasally targeted dry powder compositions and methods for their use in the treatment of exposure to organophosphate compounds including chemical warfare agents and pesticides. Compositions include anticholinergic agents and cholinesterase reactivator agents used for primary treatment and vasoactive agents and benzodiazepines used for secondary treatment of exposure, and combinations of these agents. Compositions incorporate excipients and enabling agents such as permeation enhancers, and optimal sizing of active pharmaceutical ingredient particle size to improve drug delivery across the nasal mucosa, stability, and resistance to heat degradation. Packaging and configuration of devices for dry powder nasal compositions enable their use by non-medical personnel in civilian mass casualty or battlefield environments.Type: GrantFiled: March 4, 2022Date of Patent: September 6, 2022Assignee: BELHAVEN BIOPHARMA, INC.Inventors: Barry Bleske, Ted William Lanpher
-
Patent number: 11369579Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).Type: GrantFiled: April 24, 2019Date of Patent: June 28, 2022Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 11351165Abstract: It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dose dependent, where the greater the induced expression of OPRK1, the greater the cytotoxicity of the chemotherapeutic agent. The increase in overall cytotoxicity is independent of the cytotoxicity of the agent that increases the expression of OPRK1, which itself has no or minimal cytotoxic effect.Type: GrantFiled: March 28, 2018Date of Patent: June 7, 2022Assignee: LDN Pharma LimitedInventors: Angus Dalgleish, Wai Lui
-
Patent number: 11311532Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.Type: GrantFiled: October 19, 2020Date of Patent: April 26, 2022Assignee: Neurocrine Biosciences, Inc.Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O'Brien
-
Patent number: 11278544Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: March 25, 2019Date of Patent: March 22, 2022Assignee: Nalpropion Pharmaceuticals LLCInventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 11273133Abstract: Dosage forms, drug delivery systems, methods related to sustained release of dextromethorphan or improved therapeutic effects. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: January 11, 2019Date of Patent: March 15, 2022Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 11234946Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: November 9, 2020Date of Patent: February 1, 2022Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 11214577Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.Type: GrantFiled: March 30, 2020Date of Patent: January 4, 2022Assignee: Humanwell Pharmaceutical USInventors: Subo Liao, Jun Yang, Jie Li, Wentao Du, Lie Li, Jinliang Lv, Zongquan Liao, Hao Zhou, Tianpeng Xie, Jianbo Yu
-
Patent number: 11207317Abstract: Methylnaltrexone nasal formulations are disclosed which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.Type: GrantFiled: October 24, 2019Date of Patent: December 28, 2021Assignee: APTAPHARMA INC.Inventor: Siva Rama K. Nutalapati
-
Patent number: 11207281Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: December 8, 2020Date of Patent: December 28, 2021Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 11202777Abstract: The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.Type: GrantFiled: October 25, 2018Date of Patent: December 21, 2021Assignee: East Carolina UniversityInventors: Kori Brewer, Stefan Clemens
-
Patent number: 11191838Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.Type: GrantFiled: May 7, 2020Date of Patent: December 7, 2021Assignee: AEGIS THERAPEUTICS, LLCInventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
-
Patent number: 11185540Abstract: Pharmaceutical compositions of one or more opioid antagonists or phosphodiesterase 5 (PDE5) inhibitors are disclosed.Type: GrantFiled: April 11, 2018Date of Patent: November 30, 2021Assignee: PARDON MY SCOTCH LLC.Inventor: Michael Anthony Pavlovich
-
Patent number: 11185509Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.Type: GrantFiled: July 28, 2017Date of Patent: November 30, 2021Assignee: Toray Industries, Inc.Inventors: Suguru Takaki, Satoshi Minakami, Kotoe Ohta
-
Patent number: 11173209Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.Type: GrantFiled: November 8, 2019Date of Patent: November 16, 2021Assignee: AEGIS THERAPEUTICS, LLCInventor: Edward T. Maggio
-
Patent number: 11139056Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.Type: GrantFiled: September 2, 2019Date of Patent: October 5, 2021Assignee: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Patent number: 11129826Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: October 14, 2020Date of Patent: September 28, 2021Assignee: AXSOME THERAPEUTICS, INC.Inventor: Herriot Tabuteau
-
Patent number: 11103581Abstract: An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.Type: GrantFiled: August 31, 2016Date of Patent: August 31, 2021Assignee: Acura Pharmaceuticals, Inc.Inventor: Robert Barnett Jones
-
Patent number: 11083794Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.Type: GrantFiled: June 11, 2020Date of Patent: August 10, 2021Assignee: Acura Pharmaceuticals, Inc.Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
-
Patent number: 11071734Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.Type: GrantFiled: March 30, 2018Date of Patent: July 27, 2021Assignee: Toray Industries, Inc.Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
-
Patent number: 11045478Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: GrantFiled: November 11, 2019Date of Patent: June 29, 2021Assignee: ESSENTIALIS, INC.Inventors: Neil M. Cowen, Khaled A. Yamout
-
Patent number: 11026939Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.Type: GrantFiled: October 19, 2020Date of Patent: June 8, 2021Assignee: Neurocrine Biosciences, Inc.Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
-
Patent number: 11014933Abstract: Non-peptide MOR opioid receptor modulators are provided. The compounds exhibit predominantly central activity and are used to treat e.g. substance use disorders, and pain.Type: GrantFiled: December 24, 2019Date of Patent: May 25, 2021Assignee: VIRGINIA COMMONWEALTH UNIVERSITYInventor: Yan Zhang
-
Patent number: 10987350Abstract: Disclosed and described is a novel dose titration procedure for administering the opioid antagonist, nalmefene, to a patient diagnosed with post-traumatic stress disorder (PTSD).Type: GrantFiled: April 25, 2018Date of Patent: April 27, 2021Inventors: Hillel Glover, Lillian Hahn
-
Patent number: 10988481Abstract: Analogues of 6 ?/?-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.Type: GrantFiled: May 16, 2017Date of Patent: April 27, 2021Assignee: Virginia Commonwealth UniversityInventors: Yan Zhang, Dana E. Selley, William Dewey, Hamid Abkarali
-
Patent number: 10973814Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: November 5, 2019Date of Patent: April 13, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 10967065Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.Type: GrantFiled: April 30, 2019Date of Patent: April 6, 2021Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hugh Smyth, Ju Du
-
Patent number: 10960077Abstract: A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.Type: GrantFiled: May 12, 2006Date of Patent: March 30, 2021Assignee: Intellipharmaceutics Corp.Inventors: Isa Odidi, Amina Odidi
-
Patent number: 10925870Abstract: Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in an amount effective to reduce or prevent fetal opioid dependence, wherein the opioid antagonist a) is orally available or delivered systemically and reaches the circulation of the pregnant subject, b) is substantially excluded from the subject's brain by the blood brain barrier, and c) penetrates the placenta and enters the fetal brain. The method also includes administering the opioid antagonist to the neonate in increasing amounts to facilitate weaning the neonate from continued opioid maintenance.Type: GrantFiled: January 6, 2017Date of Patent: February 23, 2021Assignee: Ohio State Innovation FoundationInventors: Wolfgang Sadee, John Oberdick
-
Patent number: 10870654Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.Type: GrantFiled: March 18, 2019Date of Patent: December 22, 2020Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Patent number: 10865186Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.Type: GrantFiled: August 22, 2018Date of Patent: December 15, 2020Assignee: Nektar TherapeuticsInventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
-
Patent number: 10828294Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: March 18, 2019Date of Patent: November 10, 2020Assignee: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Patent number: 10806731Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: April 25, 2019Date of Patent: October 20, 2020Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel R. Deaver, Elliot Ehrich
-
Patent number: 10799545Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailability of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the transdermal patch of reservoir type is also taught, which enables things such as Vitamin B12 to become part of the complex deliverable by the inventions.Type: GrantFiled: April 29, 2019Date of Patent: October 13, 2020Assignee: Remy Biosciences, Inc.Inventor: Ludwig Weimann
-
Patent number: 10744132Abstract: An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.Type: GrantFiled: September 12, 2017Date of Patent: August 18, 2020Assignee: Alar Pharmaceuticals, Inc.Inventors: Tong-Ho Lin, Yung-Shun Wen, Jui-Wei Liang
-
Patent number: 10702480Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: GrantFiled: May 9, 2014Date of Patent: July 7, 2020Assignee: OHEMO Life Sciences, Inc.Inventors: Manish S. Shah, Ray J. DiFalco
-
Patent number: 10695342Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.Type: GrantFiled: February 13, 2017Date of Patent: June 30, 2020Assignees: ALBANY MOLECULAR RESEARCH, INC., 3ST RESEARCH LLCInventors: Matthew Surman, John K. Thottathil, Kathryn Golden, Paolo Pasetto, Xiaomin Jin, Xiaowu Jiang, Fatoumata Camara
-
Patent number: 10695324Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.Type: GrantFiled: September 30, 2019Date of Patent: June 30, 2020Assignee: Washington UniversityInventors: Fumihiko Urano, Simin Lu
-
Patent number: 10695343Abstract: A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.Type: GrantFiled: October 8, 2018Date of Patent: June 30, 2020Inventors: Noreen Griffin, Fengping Shan, Nicholas Plotnikoff
-
Patent number: 10696684Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: November 20, 2019Date of Patent: June 30, 2020Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P, RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 10689389Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: August 30, 2019Date of Patent: June 23, 2020Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 10653632Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.Type: GrantFiled: February 28, 2012Date of Patent: May 19, 2020Assignee: Monash UniversityInventors: David Morton, Laurence Orlando, Tony Qi Zhou, Louise Chia-Hua Ho
-
Patent number: 10638786Abstract: Methods and compositions are provided directed to decreasing visceral fat in subjects. Visceral fat is directly linked to cardiovascular and metabolic disease risk. The methods describe a calorie restricted diet of specific percentages of food elements to be consumed within a specific time period each day. Calorie restriction and nutrient percentages take into consideration average daily normal activity of subjects as well as baseline health metrics including estimated amount of visceral fat. Remarkable results are obtained since visceral fat is targeted for reduction, thereby markedly reducing the risk of cardiovascular and metabolic disease.Type: GrantFiled: August 16, 2017Date of Patent: May 5, 2020Assignee: Zolighter, LLCInventors: Jessica Barnes, Gerald Dembrowski
-
Patent number: 10632205Abstract: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.Type: GrantFiled: May 29, 2015Date of Patent: April 28, 2020Assignee: INTELLIPHARMACEUTICS CORPInventors: Isa Odidi, Amina Odidi